Compile Data Set for Download or QSAR
Report error Found 213 Enz. Inhib. hit(s) with all data for entry = 11494
TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620558(US20230303513, Example 9 | US20230303513, Example ...)
Affinity DataEC50:  0.100nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620563(US20230303513, Example 42 | US20230303513, Example...)
Affinity DataEC50:  0.100nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620556(US20230303513, Example 4)
Affinity DataEC50:  0.100nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620557(US20230303513, Example 16 | US20230303513, Example...)
Affinity DataEC50:  0.200nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620567(US20230303513, Example 18 | US20230303513, Example...)
Affinity DataEC50:  0.200nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620645(US20230303513, Example 87 | US20230303513, Example...)
Affinity DataEC50:  0.300nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620593(US20230303513, Example 53 | US20230303513, Example...)
Affinity DataEC50:  0.300nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620642(US20230303513, Example 84 | US20230303513, Example...)
Affinity DataEC50:  0.300nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620580(US20230303513, Example 21)
Affinity DataEC50:  0.400nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620558(US20230303513, Example 9 | US20230303513, Example ...)
Affinity DataEC50:  0.400nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620655(US20230303513, Example 97 | US20230303513, Example...)
Affinity DataEC50:  0.400nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620559(US20230303513, Example 7)
Affinity DataEC50:  0.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620603(US20230303513, Example 55 | US20230303513, Example...)
Affinity DataEC50:  0.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620562(US20230303513, Example 31 | US20230303513, Example...)
Affinity DataEC50:  0.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620560(US20230303513, Example 8)
Affinity DataEC50:  0.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620596(US20230303513, Example 41 | US20230303513, Example...)
Affinity DataEC50:  0.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620576(US20230303513, Example 20 | US20230303513, Example...)
Affinity DataEC50:  0.600nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620560(US20230303513, Example 8)
Affinity DataEC50:  0.600nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620562(US20230303513, Example 31 | US20230303513, Example...)
Affinity DataEC50:  0.700nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620559(US20230303513, Example 7)
Affinity DataEC50:  0.700nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620558(US20230303513, Example 9 | US20230303513, Example ...)
Affinity DataEC50:  0.700nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620566(US20230303513, Example 19 | US20230303513, Example...)
Affinity DataEC50:  0.800nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620564(US20230303513, Example 13 | US20230303513, Example...)
Affinity DataEC50:  0.800nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620563(US20230303513, Example 42 | US20230303513, Example...)
Affinity DataEC50:  0.800nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620640(US20230303513, Example 82 | US20230303513, Example...)
Affinity DataEC50:  0.800nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620564(US20230303513, Example 13 | US20230303513, Example...)
Affinity DataEC50:  0.900nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620636(US20230303513, Example 78 | US20230303513, Example...)
Affinity DataEC50:  1nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620642(US20230303513, Example 84 | US20230303513, Example...)
Affinity DataEC50:  1nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620653(US20230303513, Example 95 | US20230303513, Example...)
Affinity DataEC50:  1.20nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620609(US20230303513, Example 50)
Affinity DataEC50:  1.20nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620616(US20230303513, Example 57)
Affinity DataEC50:  1.20nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620597(US20230303513, Example 38)
Affinity DataEC50:  1.30nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620564(US20230303513, Example 13 | US20230303513, Example...)
Affinity DataEC50:  1.30nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620566(US20230303513, Example 19 | US20230303513, Example...)
Affinity DataEC50:  1.40nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620645(US20230303513, Example 87 | US20230303513, Example...)
Affinity DataEC50:  1.40nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620642(US20230303513, Example 84 | US20230303513, Example...)
Affinity DataEC50:  1.40nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620605(US20230303513, Example 46)
Affinity DataEC50:  1.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620567(US20230303513, Example 18 | US20230303513, Example...)
Affinity DataEC50:  1.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620580(US20230303513, Example 21)
Affinity DataEC50:  1.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620640(US20230303513, Example 82 | US20230303513, Example...)
Affinity DataEC50:  1.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620660(US20230303513, Example 101)
Affinity DataEC50:  1.60nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620653(US20230303513, Example 95 | US20230303513, Example...)
Affinity DataEC50:  1.60nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620563(US20230303513, Example 42 | US20230303513, Example...)
Affinity DataEC50:  1.70nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620557(US20230303513, Example 16 | US20230303513, Example...)
Affinity DataEC50:  1.70nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620576(US20230303513, Example 20 | US20230303513, Example...)
Affinity DataEC50:  1.70nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620567(US20230303513, Example 18 | US20230303513, Example...)
Affinity DataEC50:  1.80nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620566(US20230303513, Example 19 | US20230303513, Example...)
Affinity DataEC50:  1.90nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620581(US20230303513, Example 22)
Affinity DataEC50:  2.10nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620585(US20230303513, Example 29 | US20230303513, Example...)
Affinity DataEC50:  2.40nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620586(US20230303513, Example 27)
Affinity DataEC50:  2.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

Displayed 1 to 50 (of 213 total ) | Next | Last >>
Jump to: